Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steg

Showing results (221-230 of 269) with videos related to

Pageof 27
Sort By:
Archives Des Maladies Du Coeur Et Des Vaisseaux|August 10, 2001
[Recommendations of the French Society of Cardiology concerning the treatment of myocardial infarction after the acute phase. Epidemiology and Prevention Group]F Delahaye, M Bory, A Cohen, et al.
Clinical Cardiology|October 10, 2019
Interleukin-18 in patients with acute coronary syndromesAxel Åkerblom, Stefan K James, Tatevik G Lakic, et al.
Heart (British Cardiac Society)|August 18, 2006
Bypassing the emergency room reduces delays and mortality in ST elevation myocardial infarction: the USIC 2000 registryP G Steg, J-P Cambou, P Goldstein, et al.
Diabetes/Metabolism Research and Reviews|April 9, 2013
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trialO Mosenzon, I Raz, B M Scirica, et al.
International Journal of Cardiology|June 27, 2020
Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trialP Deharo, G Ducrocq, C Bode, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|June 1, 2000
[Recommendations of the French Cardiac Society concerning the education of physicians performing coronarography and angioplasty, organization and equipment of coronarography and coronary angioplasty centers]P Meyer, P Barragan, D Blanchard, et al.
BMC Public Health|September 20, 2011
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA StudyEliseo Guallar, José R Banegas, Elena Blasco-Colmenares, et al.
JAMA Cardiology|August 7, 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, et al.
American Heart Journal|September 24, 2016
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarctionC Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|April 14, 2010
Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) RegistryT A Winkel, S E Hoeks, O Schouten, et al.
Pageof 27

Showing results (221-230 of 269) with videos related to

Sort By:
Pageof 27
Archives Des Maladies Du Coeur Et Des Vaisseaux|August 10, 2001
[Recommendations of the French Society of Cardiology concerning the treatment of myocardial infarction after the acute phase. Epidemiology and Prevention Group]F Delahaye, M Bory, A Cohen, et al.
Clinical Cardiology|October 10, 2019
Interleukin-18 in patients with acute coronary syndromesAxel Åkerblom, Stefan K James, Tatevik G Lakic, et al.
Heart (British Cardiac Society)|August 18, 2006
Bypassing the emergency room reduces delays and mortality in ST elevation myocardial infarction: the USIC 2000 registryP G Steg, J-P Cambou, P Goldstein, et al.
Diabetes/Metabolism Research and Reviews|April 9, 2013
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trialO Mosenzon, I Raz, B M Scirica, et al.
International Journal of Cardiology|June 27, 2020
Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trialP Deharo, G Ducrocq, C Bode, et al.
Archives Des Maladies Du Coeur Et Des Vaisseaux|June 1, 2000
[Recommendations of the French Cardiac Society concerning the education of physicians performing coronarography and angioplasty, organization and equipment of coronarography and coronary angioplasty centers]P Meyer, P Barragan, D Blanchard, et al.
BMC Public Health|September 20, 2011
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA StudyEliseo Guallar, José R Banegas, Elena Blasco-Colmenares, et al.
JAMA Cardiology|August 7, 2020
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol GuidelinesNicholas A Marston, Marc P Bonaca, Petr Jarolim, et al.
American Heart Journal|September 24, 2016
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarctionC Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|April 14, 2010
Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) RegistryT A Winkel, S E Hoeks, O Schouten, et al.
Pageof 27